796.60
-6.00
(-0.75%)
At close: January 30 at 5:24:48 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
8/31/2021
8/31/2020
Operating cash flow
-7,919.00
-10,295.00
-27,918.00
-21,181.00
-12,440.00
Investing cash flow
120,390.00
-73,038.00
30,211.00
-23,764.00
4,626.00
Financing cash flow
-75,841.00
51,978.00
10,779.00
102,892.00
23,786.00
End cash position
42,098.00
9,055.00
40,464.00
77,245.00
19,296.00
Income tax paid supplemental data
--
--
100.00
--
--
Interest paid supplemental data
2,876.00
574.00
--
--
--
Capital expenditure
-10.00
-254.00
-496.00
-375.00
-82.00
Issuance of capital stock
--
2,428.00
11,500.00
79,983.00
23,773.00
Issuance of debt
--
99,550.00
--
--
--
Repayment of debt
-74,550.00
-50,000.00
--
--
--
Free cash flow
-7,929.00
-10,549.00
-28,414.00
-21,556.00
-12,522.00
8/31/2020 - 7/13/2017
Upgrade to start utilising 40 years of financial statements and gain so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets and cash flows - all exportable.
UpgradeRelated tickers
LCTX.TA Lineage Cell Therapeutics, Inc.
223.00
-5.55%
PPBT.TA Purple Biotech Ltd
5.90
-4.84%
ENLV.TA Enlivex Therapeutics Ltd.
396.00
-0.63%
BLRX.TA BioLineRx Ltd.
2.4000
-25.00%
XTLB XTL Biopharmaceuticals Ltd.
1.5899
-1.25%
PPBT Purple Biotech Ltd
3.2500
-3.85%
ENLV Enlivex Therapeutics Ltd.
1.1000
-0.90%
BCLI Brainstorm Cell Therapeutics Inc.
1.8200
-6.19%
IVVD Invivyd, Inc.
0.3577
-8.28%
CGEN Compugen Ltd.
2.3300
-0.85%